Therapy Detail

Therapy Name Pegylated liposomal-doxorubicin + Veliparib
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pegylated liposomal-doxorubicin Doxil ATI-0918|CAELYX Chemotherapy - Anthracycline 11 Doxil (pegylated liposomal doxorubicin) is doxorubicin encapsulated within a liposome to allow better penetration into tumors, decrease toxicity, and increase the period of effectiveness. Doxorubicin intercalates into DNA, disrupting DNA replication (NCI Drug Dictionary). Doxil (pegylated liposomal doxorubicin) is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma (FDA.gov).
Veliparib ABT-888 PARP Inhibitor (Pan) 17 Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01145430 Phase I Pegylated liposomal-doxorubicin + Veliparib Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Completed